Global Stem Cells Market by Products (Adult Stem Cells, Human Embryonic Stem Cells, Induced Pluripotent Stem Cells and Very Small Embryonic Like Stem Cells) by Applications (Regenerative Medicine, Drug Discovery and Development) by Therapy (Autologous Stem Cells Therapy, Allogenic Stem Cells Therapy) - Market Growth, Future Prospects & Competitive Analysis, 2017 – 2025

To accelerate stem cell technology in perspective of drug discovery and development the pharmaceutical giants are currently focusing on integrating differentiation pathway discovery in non-human and human systems, stem cells training courses and institutional core facilities and developing stem cells gene tagged libraries. Additionally optimization of the cellular models and designs of stem cells employed are taking place with special focus on euploid, developmentally manipulative human models, probe mechanistic and phenotypic robustness of the natural genetic variation.

For the purpose of this study, the various products studied includes adult stem cells, human embryonic stem cells, induced pluripotent stem cells, very small embryonic like stem cells. Adult stem cells are further classified as (neuronal stem cells, hematopoietic stem cells, mesenchymal stem cells, umbilical cord stem cells and others). The applications are classified as regenerative medicines and drug discovery and development. Regenerative medicines are further categorized as (neurology, orthopedics, oncology, hematology, cardiovascular diseases, diabetes, liver disorders and others). Therapy segment is further categorized as autologous stem cells therapy and allogenic stem cells therapy. Market size estimates and forecast of these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global stem cells market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global stem cells market. The key players profiled in this report are Advanced Cell Technology, Inc., BIOTIME, Inc., BrainStorm Cell Therapeutics, Caladrius, Cellartis AB, Celgene Corporation, CellGenix GmbH, Gamida Cell, Genea BioCells, Lonza, PromoCell GmbH, Pluristem, TiGenix and Waisman Biomanufacturing.

The stem cell market is driven by factors such as rising demand for epigenetics for drug discovery and development, and development of cellular models to provide better understanding of disease mechanism. In addition the stem cells are a repository of information regarding the cellular differentiation, tissue homeostasis, and molecular processes. In 2016, adult stem cells segment held the largest market share mainly due to factors such as high compatibility with human body, low contamination while subculturing and other advantages such as avoiding ethical issues associated with the use of other human cells. Induced pluripotent stem cells will be the fastest growing market throughout the forecast period 2017-2025 majorly due to its application in regenerative medicines, drug screening, disease modelling and organoid generation. The major players in stem cell market are Advanced Cell Technology, Inc., BIOTIME, Inc., BrainStorm Cell Therapeutics, Caladrius, Cellartis AB, Celgene Corporation, CellGenix GmbH, Gamida Cell, Genea BioCells, Lonza, PromoCell GmbH, Pluristem, TiGenix and Waisman Biomanufacturing.

In 2016, regenerative medicine dominated the market mainly due to factors such as rising prevalence of chronic disease requiring immediate medical intervention, and it provides novel opportunities to the pharmaceutical companies by identification of lead candidate and development of novel drugs. In addition, there is supportive regulatory environment for the utilization of stem cells as regenerative medicine. The drug discovery and development segment is anticipated to register faster growth throughout the forecast period 2017-2025, mainly due to increasing demand for stem cell technology by the pharmaceutical giants to reduce the high attrition rate of late stage drug candidates and build innovative cellular models. Moreover, the constantly evolving methodologies for the isolation of stem cells has led to the advancement of high throughput and combinatorial screening technologies thus supplementing in drug discovery and development.

In 2016, the autologous stem cell therapy segment held the largest market share chiefly due to factors such as high body compatibility, no immunological rejection. Additionally it can take place outside the operating room without giving anesthesia. The limitation of the autologous stem cell therapy are that the patient needs to be in close proximity of the hospital or research center, it is a non-scalable technique and enrolls only small patient population. Allogenic stem cell therapy will be the fastest growing market throughout the forecast period 2017-2025 majorly due to its application in oncology as it gives the graft versus cancer effect in which the donor cells make their own immune cells which helps in destroying any cancer cells remaining after high dose treatment. Additionally the donor could be asked to donate more stem cells and white blood cells whenever required. The limitation of this therapy is the graft versus host disease where the donor immune cells attacks the host healthy cells and the risk of infection even though the donors are tested before, as the infections surface after the allogenic transplant as the host immune system is suppressed due to immunosuppressive drugs.

North America was observed to be the largest market for stem cells in the base year 2016. The dominance of North America is mainly attributed to the rising prevalence of chronic diseases, enhanced government spending in the research and development facilities in healthcare institutions and affordable reimbursement scenario. The market growth in Europe is mainly attributed to the rising demand for epigenetics and its application in biomedical science. Increasing popularity of personalized medication and large number of clinical trials conducted on therapeutic application of stem cells in treating hematological disorders. Asia Pacific was observed as the fastest growing regional segment throughout the forecast period 2017-2025. Factors that are anticipated to propel the market growth are presence of geriatric population suffering with chronic diseases requiring immediate medical intervention, technological advancement in the extraction and harvesting of stem cells for therapeutic applications and supportive regulatory environment for stem cells products. Moreover, factors such as developing health infrastructure, untapped market in remote areas with unmet medical needs are going to fuel the rapid growth of stem cells market in Latin America, and Middle East and Africa in the near future.   

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Stem Cells market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Stem Cells market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Stem Cells market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Stem Cells market?
• Which is the largest regional market for Stem Cells market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Stem Cells market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Stem Cells market worldwide?